FUNCTIONAL CHARACTERIZATION OF FIVE NOVEL CYP2C8 VARIANTS, G171S, R186X, R186G, K247R, AND K383N, FOUND IN A JAPANESE POPULATION
Authors:
- Toshiko Tanaka-KagawaTTToshiko Tanaka-Kagawa
- Akiko SoyamaASAkiko Soyama
- Hideto JinnoHJHideto Jinno
- Satoru KoyanoSKSatoru Koyano
- Noriko KatoriNKNoriko Katori
- Erika MatsushimaEMErika Matsushima
- Shigehisa UchiyamaSUShigehisa Uchiyama
- Hiroshi TokunagaHTHiroshi Tokunaga
- Hideo KimuraHKHideo Kimura
- Narihiro MinamiNMNarihiro Minami
- Masaaki KatohMKMasaaki Katoh
- 1 May 2005
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 33 (5) , 630-636
Abstract
Cytochrome P450 2C8 is one of the primary enzymes responsible for the metabolism of a wide range of drugs such as paclitaxel, cerivastatin, and amiodarone. We have sequenced the CYP2C8 gene from 201 Japanese subjects and found five novel nonsynonymous single nucleotide polymorphisms (SNPs): 511G>A (G171S), 556C>T (R186X; X represents the translational stop codon), 556C>G (R186G), 740A>G (K247R), and 1149G>T (K383N), with the allele frequency of 0.0025. The CYP2C8 variants were heterologously expressed in COS-1 cells and functionally characterized in terms of expression level, paclitaxel 6α-hydroxylase activity, and intracellular localization. The prematurely terminated R186X variant was undetectable by Western blotting and inactive toward paclitaxel 6α-hydroxylation. The G171S, K247R, and K383N variants exhibited properties similar to those of the wild-type CYP2C8. Paclitaxel 6α-hydroxylase activity of the R186G transfectant was only 10 to 20% that of wild-type CYP2C8. Furthermore, the R186G variant displayed a lower level of protein expression in comparison to the wild type, which was restored by the addition of a proteasome inhibitor (MG-132; Z-Leu-Leu-Leu-aldehyde). The reduced CO-difference spectral analysis using recombinant proteins from an insect cell/baculovirus system revealed that the R186G variant has a minor peak at 420 nm in addition to the characteristic Soret peak at 450 nm, suggesting the existence of improperly folded protein. These results indicate that the novel CYP2C8 SNPs, 556C>T (R186X) and 556C>G (R186G), could influence the metabolism of CYP2C8 substrates such as paclitaxel and cerivastatin.Keywords
This publication has 31 references indexed in Scilit:
- Proteasomal Degradation of Human CYP1B1: Effect of the Asn453Ser Polymorphism on the Post-Translational Regulation of CYP1B1 ExpressionMolecular Pharmacology, 2005
- CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinideBritish Journal of Clinical Pharmacology, 2003
- Functional characterization of three human cytochrome P450 2E1 variants with amino acid substitutionsXenobiotica, 2003
- Hepatic Cytochrome P450 Degradation: Mechanistic Diversity of the Cellular Sanitation BrigadeDrug Metabolism Reviews, 2003
- CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomesBiochemical Pharmacology, 2002
- Regioselective Metabolism of Taxoids by Human CYP3A4 and 2C8: Structure-Activity RelationshipDrug Metabolism and Disposition, 2002
- Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acidPharmacogenetics, 2001
- In Vitro Metabolism1999
- Complete cDNA Sequence and cDNA-Directed Expression of CYP4A11, a Fatty Acid ω-Hydroxylase Expressed in Human KidneyDNA and Cell Biology, 1993
- [9] Expression of mammalian cytochrome P450 using baculovirus1991